从坦桑尼亚分离出的产VIM-2型铜绿假单胞菌与序列类型244和640以及blaVIM-2在TniC整合子中的位置有关。
Identification of VIM-2-producing Pseudomonas aeruginosa from Tanzania is associated with sequence types 244 and 640 and the location of blaVIM-2 in a TniC integron.
作者信息
Moyo Sabrina, Haldorsen Bjørg, Aboud Said, Blomberg Bjørn, Maselle Samuel Y, Sundsfjord Arnfinn, Langeland Nina, Samuelsen Ørjan
机构信息
Department of Clinical Science, University of Bergen, Bergen, Norway Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.
出版信息
Antimicrob Agents Chemother. 2015 Jan;59(1):682-5. doi: 10.1128/AAC.01436-13. Epub 2014 Oct 20.
Abstract
Epidemiological data on carbapenemase-producing Gram-negative bacteria on the African continent are limited. Here, we report the identification of VIM-2-producing Pseudomonas aeruginosa isolates in Tanzania. Eight out of 90 clinical isolates of P. aeruginosa from a tertiary care hospital in Dar es Salaam were shown to harbor bla(VIM-2). The bla(VIM-2)-positive isolates belonged to two different sequence types (ST), ST244 and ST640, with bla(VIM-2) located in an unusual integron structure lacking the 3' conserved region of qacΔE1-sul1.
摘要
非洲大陆上产碳青霉烯酶革兰氏阴性菌的流行病学数据有限。在此，我们报告在坦桑尼亚鉴定出产VIM-2的铜绿假单胞菌分离株。来自达累斯萨拉姆一家三级护理医院的90株铜绿假单胞菌临床分离株中，有8株被证明携带bla(VIM-2)。bla(VIM-2)阳性分离株属于两种不同的序列类型（ST），即ST244和ST640，bla(VIM-2)位于一个不寻常的整合子结构中，该结构缺乏qacΔE1-sul1的3'保守区域。
相似文献
1
Identification of VIM-2-producing Pseudomonas aeruginosa from Tanzania is associated with sequence types 244 and 640 and the location of blaVIM-2 in a TniC integron.
Antimicrob Agents Chemother. 2015 Jan;59(1):682-5. doi: 10.1128/AAC.01436-13. Epub 2014 Oct 20.
2
Characterization of acquired beta-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: the prevalence of unusual integrons.
J Antimicrob Chemother. 2006 Sep;58(3):530-6. doi: 10.1093/jac/dkl266. Epub 2006 Jul 1.
3
Carbapenemase-producing Pseudomonas aeruginosa from central Greece: molecular epidemiology and genetic analysis of class I integrons.
BMC Infect Dis. 2013 Oct 29;13:505. doi: 10.1186/1471-2334-13-505.
4
Molecular analysis of the integrons of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan.
BMC Microbiol. 2015 Feb 21;15:41. doi: 10.1186/s12866-015-0378-8.
5
Analysis of a novel class 1 integron containing metallo-beta-lactamase gene VIM-2 in Pseudomonas aeruginosa.
J Microbiol. 2009 Dec;47(6):753-9. doi: 10.1007/s12275-008-0272-2. Epub 2010 Feb 4.
6
bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital.
Antimicrob Agents Chemother. 2002 Apr;46(4):1053-8. doi: 10.1128/AAC.46.4.1053-1058.2002.
7
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
Antimicrob Agents Chemother. 2008 Oct;52(10):3589-96. doi: 10.1128/AAC.00465-08. Epub 2008 Jul 21.
8
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
Antimicrob Agents Chemother. 2010 Jan;54(1):346-52. doi: 10.1128/AAC.00824-09. Epub 2009 Nov 2.
9
Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying bla, bla, bla, bla and bla.
Int J Antimicrob Agents. 2020 Jul;56(1):106026. doi: 10.1016/j.ijantimicag.2020.106026. Epub 2020 May 22.
10
[VIM-2 metallo-ß-lactamase gen detection in a class 1 integron associated to bla(CTX-M-2) in a Pseudomonas aeruginosa clinical isolate in Uruguay: first communication].
Rev Argent Microbiol. 2011 Jul-Sep;43(3):198-202. doi: 10.1590/S0325-75412011000300004.
引用本文的文献
1
High-risk clones harboring β-lactamases: 2024 update.
Heliyon. 2024 Dec 26;11(1):e41540. doi: 10.1016/j.heliyon.2024.e41540. eCollection 2025 Jan 15.
2
Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana.
PLoS One. 2023 Oct 30;18(10):e0274156. doi: 10.1371/journal.pone.0274156. eCollection 2023.
3
Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
Eur J Clin Microbiol Infect Dis. 2023 Jan;42(1):61-66. doi: 10.1007/s10096-022-04526-0. Epub 2022 Nov 15.
4
First identification of producing from neonates and a HIV infected adult in Tanzania.
J Med Microbiol. 2022 Feb;71(2). doi: 10.1099/jmm.0.001513.
5
Incidence and Molecular Characterization of Carbapenemase Genes in Association with Multidrug-Resistant Clinical Isolates of Pseudomonas aeruginosa from Tertiary Healthcare Facilities in Southwest Nigeria.
Curr Microbiol. 2021 Dec 14;79(1):27. doi: 10.1007/s00284-021-02706-3.
6
Mobile Carbapenemase Genes in .
Front Microbiol. 2021 Feb 18;12:614058. doi: 10.3389/fmicb.2021.614058. eCollection 2021.
7
Detection of diverse carbapenem and multidrug resistance genes and high-risk strain types among carbapenem non-susceptible clinical isolates of target gram-negative bacteria in Kenya.
PLoS One. 2021 Feb 22;16(2):e0246937. doi: 10.1371/journal.pone.0246937. eCollection 2021.
8
Carbapenemase-Producing Non-Glucose-Fermenting Gram-Negative Bacilli in Africa, and : A Systematic Review and Meta-Analysis.
Int J Microbiol. 2020 Nov 3;2020:9461901. doi: 10.1155/2020/9461901. eCollection 2020.
9
Molecular Epidemiology of Multi-Drug Resistant Isolates from Hospitalized Patients in Greece.
Microorganisms. 2020 Oct 24;8(11):1652. doi: 10.3390/microorganisms8111652.
10
Genetic diversity and risk factors for the transmission of antimicrobial resistance across human, animals and environmental compartments in East Africa: a review.
Antimicrob Resist Infect Control. 2020 Aug 6;9(1):127. doi: 10.1186/s13756-020-00786-7.
本文引用的文献
1
Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio.
Antimicrob Agents Chemother. 2014 Oct;58(10):5929-35. doi: 10.1128/AAC.02372-14. Epub 2014 Jul 28.
2
Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.
J Antimicrob Chemother. 2014 Jul;69(7):1804-14. doi: 10.1093/jac/dku048. Epub 2014 Mar 5.
3
Comparison of local features from two Spanish hospitals reveals common and specific traits at multiple levels of the molecular epidemiology of metallo-β-lactamase-producing Pseudomonas spp.
Antimicrob Agents Chemother. 2014;58(4):2454-8. doi: 10.1128/AAC.02586-13. Epub 2014 Feb 3.
4
Carbapenemase-producing Pseudomonas aeruginosa from central Greece: molecular epidemiology and genetic analysis of class I integrons.
BMC Infect Dis. 2013 Oct 29;13:505. doi: 10.1186/1471-2334-13-505.
5
Outbreak of metallo-β-lactamase VIM-2-positive strains of Pseudomonas aeruginosa in the Ivory Coast.
J Antimicrob Chemother. 2013 Dec;68(12):2952-4. doi: 10.1093/jac/dkt296. Epub 2013 Jul 25.
6
Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study.
Lancet Infect Dis. 2013 Oct;13(10):867-76. doi: 10.1016/S1473-3099(13)70168-3. Epub 2013 Jul 9.
7
Dissemination of metallo-β-lactamase-producing Pseudomonas aeruginosa of sequence type 235 in Asian countries.
J Antimicrob Chemother. 2013 Dec;68(12):2820-4. doi: 10.1093/jac/dkt269. Epub 2013 Jul 9.
8
Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals.
Microb Drug Resist. 2013 Oct;19(5):355-61. doi: 10.1089/mdr.2013.0004. Epub 2013 Apr 21.
9
"Stormy waters ahead": global emergence of carbapenemases.
Front Microbiol. 2013 Mar 14;4:48. doi: 10.3389/fmicb.2013.00048. eCollection 2013.
10
Dissemination of a class I integron carrying VIM-2 carbapenemase in Pseudomonas aeruginosa clinical isolates from a hospital intensive care unit in Annaba, Algeria.
Antimicrob Agents Chemother. 2013 May;57(5):2426-7. doi: 10.1128/AAC.00032-13. Epub 2013 Mar 4.
Zotero 插件